Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
109 hedge funds and large institutions have $1.29B invested in Day One Biopharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 39 increasing their positions, 25 reducing their positions, and 7 closing their positions.
243% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 7
56% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 25
17% more funds holding
Funds holding: 93 → 109 (+16)
8% more capital invested
Capital invested by funds: $1.19B → $1.29B (+$99.7M)
0.88% less ownership
Funds ownership: 82.72% → 81.84% (-0.88%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
33% less call options, than puts
Call options by funds: $2.98M | Put options by funds: $4.43M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pathway Capital Management
Irvine,
California
|
+$12.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.1M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$9.72M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.47M |
| 5 |
State Street
Boston,
Massachusetts
|
+$8.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPX
Canaan Partners XI
Menlo Park,
California
|
-$90.6M |
| 2 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$12.3M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$8.01M |
| 4 |
BlackRock
New York
|
-$2.17M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$1.68M |
DAWN Hedge Fund Activity: Q4 2022 in Review
109 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q4 2022, worth a combined $1.29B — up 8.4% from $1.19B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new DAWN positions and 7 closed out — a net gain of 17 holders — while 39 added to existing stakes and 25 trimmed.
The largest buyer was Pathway Capital Management, adding an estimated $12.2M. The largest seller was Canaan Partners XI, cutting an estimated $90.6M.
- 109 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q4 2022, up from 93 in Q3 2022.
- Funds reported $1.29B of Day One Biopharmaceuticals stock for Q4 2022, up 8.4% quarter-over-quarter.
- 24 funds opened new Day One Biopharmaceuticals positions in Q4 2022 and 7 closed out, a net change of +17 holders.
- The largest Day One Biopharmaceuticals buyer in Q4 2022 was Pathway Capital Management, an estimated $12.2M added.
- The largest Day One Biopharmaceuticals seller in Q4 2022 was Canaan Partners XI, an estimated $90.6M sold.
Based on aggregated 13F filings for Q4 2022.